Figure 2.
Design and outcomes of phase II trials SPRINT (Serine Protease Inhibitor Therapy) and PROVE (Protease Inhibitor for Viral Evaluation) studies of boceprevir (BOC) and telaprevir (TVR). PIFN indicates peginterferon alfa; R, ribavirin; SOC, standard of care (peginterferon alfa and ribavirin); SVR, sustained virologic response. Compiled from McHutchison et al, Hezode et al, and Kwo et al.13-15